
561P	E 45.43
MAR i	5 2002





SHEET __1_ OF __1

OF 14 19 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY, DOCKET NO. 4147-23-1 SERIAL NO 10/040.572

APPLICANT BATHURST et al

FILING DATE January 4, 2002

GROUP ART 1651 MAR 1 9 200

TECH CENTER 1600-290

U.S PATENT DOCUMENTS

*E.KAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP
	AA	6.004.579	12/21/99	BATHURST ET AL.			
	АВ	5,635,187	6/3/97	BATHURST ET AL.			
	AC	5.075.113	12/24/91	DUBOIS			
	AD	4,530.788	7/23/85	CHANG			<u></u>

FOREIGN PATENT DOCUMENTS

				SUB	TRANSL	3
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
					<u>L</u>	ليبا

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

		1975 C				۶
⊩	ΑE	Kumazawa et ai , 1985. Cancer Immunology Immuntherapy, 19(2):79-84.		III	2	्र
	AF	Bathurst et al., 1998, Pharmaceutical Biology, 36(2):111-123.		5	8	_
	AG			-	•	_ੁ
				Щ		<u> </u>
ــــــــــــــــــــــــــــــــــــــ				\overline{C}		~
			Į.	Ш		ਠ
			ί	r		ਨੰ
						1.1.1

-AMINER	DATE CONSIDERED
	d

*E CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.